Moneycontrol
Oct 12, 2017 01:20 PM IST | Source: Moneycontrol.com

Zydus receives final approval from USFDA for Desvenlafaxine extended-release tablets

Zydus Cadila has received final approval from the USFDA to market Desvenlafaxine extended-release tablets, 50 mg and 100 mg.

Zydus receives final approval from USFDA for Desvenlafaxine extended-release tablets

Zydus Cadila has received final approval from the USFDA to market Desvenlafaxine extended-release tablets, 50 mg and 100 mg.

At 13:15 hrs Cadila Healthcare was quoting at Rs 497.45, up Rs 6.10, or 1.24 percent.

The share touched its 52-week high Rs 558.00 and 52-week low Rs 342.00 on 12 June, 2017 and 26 December, 2016, respectively.

Currently, it is trading 10.85 percent below its 52-week high and 45.45 percent above its 52-week low.

Market capitalisation stands at Rs 50,926.08 crore. Source : BSE
X
Sections
Follow us on
Available On